Saladax is dedicated to the development of in vitro diagnostic assays that enable personalized treatment of patients with the goal of improved treatment efficacy and/or reduced toxicity. .
Our initial focus is in the oncology field, with assays that measure chemotherapy drug levels in plasma using proprietary monoclonal antibodies bound to nanoparticles. The majority of these antibodies are the first ever developed to the drugs in question. The practice of Therapeutic Drug Management (TDM) is routine in many fields of medicine, including neurology, 
cardiology, and transplantation, but it has not been prevalent in oncology. Typically, the criteria used to select drugs as good monitoring candidates apply very aptly to chemotherapy agents. These include:
• A highly variable relationship between dose and resulting individual blood concentration
• A relationship between the drug blood concentration and the desired and/or undesired effect
• A narrow therapeutic window (i.e., the level at which the drug is effective is very close to the level at which it is toxic), and
• A narrow toxicity profile or "dose-limiting toxicity".
Saladax is developing a pipeline of dose management assays for chemotherapy drugs that meet these criteria, with 5-fluorouracil being the first to become available to the oncology community.
FOR ADDITIONAL INFORMATION ON ANY SALADAX PRODUCTS, PLEASE CONTACT:
Keith GallowayVice President, Marketing & Sales
Saladax Biomedical, Inc
116 Research Drive
Bethlehem, PA 18015
E-mail:
kgalloway@saladax.comPhone: (610) 419-6731 ext 26517
Fax: (610) 849-5001